Rebamipide

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Rebamipide
Accession Number
DB11656
Description

Rebamipide has been investigated for the treatment of Stomach Ulcer, Keratoconjunctivitis Sicca, and Gastric Adenoma and Early Gastric Cancer.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 370.79
Monoisotopic: 370.0720347
Chemical Formula
C19H15ClN2O4
Synonyms
  • Rebamipida
  • Rebamipide
  • Rébamipide
  • Rebamipidum
External IDs
  • OPC 12759
  • OPC-12759

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

International/Other Brands
Mucosta

Categories

ATC Codes
A02BX14 — Rebamipide
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as hippuric acids. These are compounds containing hippuric acid, which consists of a of a benzoyl group linked to the N-terminal of a glycine.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Hippuric acids
Alternative Parents
N-acyl-alpha amino acids / Quinolones and derivatives / Hydroxyquinolines / 4-halobenzoic acids and derivatives / Benzoyl derivatives / Hydroxypyridines / Chlorobenzenes / Aryl chlorides / Heteroaromatic compounds / Secondary carboxylic acid amides
show 9 more
Substituents
4-halobenzoic acid or derivatives / Alpha-amino acid or derivatives / Aromatic heteropolycyclic compound / Aryl chloride / Aryl halide / Azacycle / Benzoyl / Carbonyl group / Carboxamide group / Carboxylic acid
show 25 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Chemical Identifiers

UNII
LR583V32ZR
CAS number
90098-04-7
InChI Key
ALLWOAVDORUJLA-UHFFFAOYSA-N
InChI
InChI=1S/C19H15ClN2O4/c20-13-7-5-11(6-8-13)18(24)22-16(19(25)26)9-12-10-17(23)21-15-4-2-1-3-14(12)15/h1-8,10,16H,9H2,(H,21,23)(H,22,24)(H,25,26)
IUPAC Name
2-[(4-chlorophenyl)formamido]-3-(2-oxo-1,2-dihydroquinolin-4-yl)propanoic acid
SMILES
OC(=O)C(CC1=CC(=O)NC2=C1C=CC=C2)NC(=O)C1=CC=C(Cl)C=C1

References

General References
Not Available
PubChem Compound
5042
PubChem Substance
347828027
ChemSpider
4866
ChEBI
93814
ChEMBL
CHEMBL1697771
Wikipedia
Rebamipide

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentDry Eye Syndromes / Sjögren's Syndrome1
4CompletedTreatmentGastric Ulcer2
4CompletedTreatmentGastritis1
4CompletedTreatmentGastritis Acute / Gastritis Chronic1
4CompletedTreatmentGastroesophageal Reflux1
4CompletedTreatmentNSAID Induced Gastropathy1
4RecruitingTreatmentDyspepsia1
3CompletedPreventionAnkylosing Spondylitis (AS) / Osteoarthritis (OA) / Rheumatoid Arthritis1
3CompletedPreventionGastric Lesion1
3CompletedTreatmentDry Eye Syndrome (DES)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Tablet, film coatedOral
Granule
Tablet100 mg
Tablet
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0103 mg/mLALOGPS
logP2.32ALOGPS
logP2.76ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)3.52ChemAxon
pKa (Strongest Basic)-1.1ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area95.5 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity98.5 m3·mol-1ChemAxon
Polarizability36.82 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00xr-0698000000-68b14bd14b18bae9a8c5

Drug created on October 20, 2016 14:37 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates